Journal
ACS NANO
Volume 16, Issue 7, Pages 10918-10930Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.2c03311
Keywords
T cell therapy; immune checkpoint; SHP2; drug delivery; lipid nanoparticles
Categories
Funding
- Innovation Fund Denmark [5164-00010B]
Ask authors/readers for more resources
Although adoptive T cell therapy for cancer treatment has limitations, loading T cells with SHP099 can enhance therapeutic efficacy. Cell-loaded SHP099 enables sustained inhibition of the PD-1/PD-L1 signaling and increases cytolytic activity of the T cells. This is a promising therapeutic strategy.
Whereas adoptive T cell therapy has been extensively studied for cancer treatment, the response is still limited primarily due to immune dysfunction related to poor cell engraftment, tumor infiltration and engagement, and lack of a target. In addition, the modification of therapeutic T cells often suffers from being complex and expensive. Here, we present a strategy to load T cells with SHP099, an allosteric SHP2 inhibitor, to enhance the therapeutic efficacy of the T cells. Remote-loading of SHP099 into lipid nanoparticles decorated with triarginine motifs resulted in nanocrystal formation of SHP099 inside the lipid vesicles and allowed high loading efficiency and prolonged retention of SHP099 nanocrystals within T cells. Cell-loaded SHP099 enabled sustained inhibition of the PD-1/PD-L1 signaling and increased cytolytic activity of the T cells. We show in a mouse model that tumor-homing T cells can circulate with the cargos, improving their tumor accumulation compared to systemically administered lipid nanoparticles. On an established solid tumor model, adoptively transferred SHP099 loaded T cells induced complete tumor eradication and durable immune memory against tumor rechallenging on all treated mice by effectively inhibiting the PD-1/PD-L1 checkpoint signal. We demonstrate that the combination of T cell therapy with SHP2 inhibition is a promising therapeutic strategy, and the lipid nanocrystal platform could be generalized as a promising approach for T cell loading of immunomodulatory drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available